According to my statistical data, the global diabetes market size was around USD40 billion during 2008-2018, wherein, insulin products accounted for about 50%.
Also read: Polyethylene Glycol Loxenatide! The First Chinese-produced Long-acting GLP-1R Agonist
According to the data of Frost & Sullivan, there were about 453 million diabetes patients worldwide in 2017, and China had the largest number; the size of Chinese diabetes drug market was about RMB51.2 billion in 2017, wherein, sales of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors reached RMB1.8 billion in China, with the market share of 3.4%; while, the sales of them reached USD17.8 billion worldwide, with the market share of 46.4%.
全球糖尿病市场份额 | Shares in the Global Diabetes Drug Market |
胰岛素 | Insulin |
其他 | Others |
It is clear that GLP-1R agonists have been rapidly expanding in recent years. According to a document of IMS in 2018, the compound annual growth rate of GLP-1R agonists reached 35.7% from 2008 to 2018, and they are still rapidly expanding at present; global sales of GLP-1R agonists reached about USD8 billion in 2018, with a market share of about 20%.
Global Sales of GLP-1R Agonists
Trade name | Generic name | Company | 2017 (USD1 million) | 2018 (USD1 million) |
Bydureon | Long-acting exenatide | AstraZeneca/BMS | 574 | 584 |
Byetta | Exenatide | Eli Lilly/BMS | 176 | 126 |
Ozempic | Semaglutide | Novo Nordisk |
| 283.8 |
Trulicity | Dulaglutide | Eli Lilly | 2,030 | 3,199 |
Victoza | Liraglutide | Novo Nordisk | 3,520.2 | 3,844.6 |
Eperzan/Tanzeum | Albiglutide | GSK | 112.1 | 41.4 |
As mentioned above, GLP-1R agonists are now flourishing and rapidly ...
(All Rights Reserved)